Intervention not reported
fatigue · Women with newly diagnosed epithelial ovarian cancer
The intervention leads to higher fatigue (high certainty).
1 finding from 1 review
Intervention not reported
gastrointestinal AEs · Women with newly diagnosed epithelial ovarian cancer
The intervention leads to higher gastrointestinal AEs (high certainty).
1 finding from 1 review
Intervention not reported
infection · Women with newly diagnosed epithelial ovarian cancer
The intervention leads to higher infection (high certainty).
1 finding from 1 review
Intervention not reported
metabolic AEs · Women with newly diagnosed epithelial ovarian cancer
The intervention leads to higher metabolic AEs (high certainty).
1 finding from 1 review
Intervention not reported
pain · Women with newly diagnosed epithelial ovarian cancer
The intervention leads to higher pain (high certainty).
1 finding from 1 review
Intervention not reported
Death from all causes · patients with early stage cervical cancer
The intervention probably leads to lower death from all causes (moderate certainty).
1 finding from 1 review
Intervention not reported
Disease progression · patients with early stage cervical cancer
The intervention probably leads to lower disease progression (moderate certainty).
1 finding from 1 review
Intervention not reported
Grade 4 toxicity3 · patients with early stage cervical cancer
The intervention probably leads to higher grade 4 toxicity3 (moderate certainty).
1 finding from 1 review
Intervention not reported
Disease progression · patients with early stage cervical cancer
The intervention showed no clear difference in disease progression (low certainty).
1 finding from 1 review
Intervention not reported
Primary cure (remission) · women withe low‐risk GTN
The intervention probably leads to lower primary cure (remission) (moderate certainty).
1 finding from 1 review
Intervention not reported
Failure of first‐line therapy · women withe low‐risk GTN
The intervention probably leads to higher failure of first‐line therapy (moderate certainty).
1 finding from 1 review
Intervention not reported
Severe adverse events (≥ grade 3) · women withe low‐risk GTN
The intervention showed no clear difference in severe adverse events (≥ grade 3) (low certainty).
1 finding from 1 review
Intervention not reported
Nausea · women withe low‐risk GTN
The intervention showed no clear difference in nausea (moderate certainty).
1 finding from 1 review
Intervention not reported
Alopecia · women withe low‐risk GTN
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Overall survival (Death) · patients with advanced and/or metastatic colorectal cancer
IRI with fluoropyrimidines showed no clear difference in overall survival (Death) compared with single agent IRI (low certainty).
1 finding from 1 review
Progression‐free survival (PSF) · patients with advanced and/or metastatic colorectal cancer
IRI with fluoropyrimidines probably leads to lower progression‐free survival (Disease progression) compared with single agent IRI (moderate certainty).
1 finding from 1 review
Grade 3/4 diarrhea · patients with advanced and/or metastatic colorectal cancer
IRI with fluoropyrimidines probably leads to lower grade 3/4 diarrhea compared with single agent IRI (moderate certainty).
1 finding from 1 review
Grade 3/4 nausea · patients with advanced and/or metastatic colorectal cancer
IRI with fluoropyrimidines showed no clear difference in grade 3/4 nausea compared with single agent IRI (low certainty).
1 finding from 1 review
Intervention not reported
Overall survival Hazard ratio · patients with resectable thoracic esophageal cancer
The intervention probably leads to lower overall survival Hazard ratio (moderate certainty).
1 finding from 1 review
Intervention not reported
Complete resection (R0) Histology · patients with resectable thoracic esophageal cancer
The intervention probably leads to higher complete resection (R0) Histology (moderate certainty).
1 finding from 1 review